Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.87 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.87 |
| ▸ | RAB9A | P51151 | 4/20 | 0.87 |
| ▸ | NPC1 | O15118 | 3/20 | 0.87 |
| ▸ | GAA | P10253 | 5/20 | 0.65 |
| ▸ | ALPL | P05186 | 1/20 | 0.65 |
| ▸ | ALPI | P09923 | 1/20 | 0.65 |
| ▸ | ALPG | P10696 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | MMP10 | P09238 | 1/20 | 0.61 |
| ▸ | MMP13 | P45452 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | APEX1 | P27695 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30018123 | 0.76 | MAPT (1.00) | MAPTKDM4ERAB9ANPC1GAA | |
| SCHEMBL880220 | 0.76 | MAPT (1.00) | MAPTKDM4ERAB9ANPC1GAA | |
| SCHEMBL15171169 | 0.74 | APEX1 (1.00) | MAPTKDM4ERAB9ANPC1GAA | |
| SCHEMBL22639804 | 0.73 | MAPT (0.62) | MAPTKDM4ERAB9ANPC1GAA | |
| SCHEMBL15558638 | 0.72 | NPC1 (0.58) | MAPTKDM4ERAB9ANPC1GAA | |
| SCHEMBL15558643 | 0.72 | NPC1 (0.58) | MAPTKDM4ERAB9ANPC1GAA | |
| SCHEMBL15762974 | 0.71 | JMJD6 (1.00) | MAPTKDM4ERAB9ANPC1GAA | |
| SCHEMBL8291377 | 0.71 | KMT2A (1.00) | MAPTKDM4ERAB9AGAAALPL | |
| SCHEMBL8480366 | 0.69 | XDH (0.54) | MAPTKDM4ERAB9ANPC1GAA | |
| SCHEMBL8480356 | 0.69 | XDH (0.54) | MAPTKDM4ERAB9ANPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11730817-B2 | Pro-cyclic dinucleotides and pro-cyclic dinucleotide conjugates for cytokine induction | INVIVOGEN (FR) | 2023-08-22 | — | — | US | disclosed |
| US-20230116913-A2 | PRO-CYCLIC DINUCLEOTIDES AND PRO-CYCLIC DINUCLEOTIDE CONJUGATES FOR CYTOKINE INDUCTION | INVIVOGEN (FR) | 2023-04-13 | — | — | US | disclosed |
| US-20220339287-A9 | PRO-CYCLIC DINUCLEOTIDES AND PRO-CYCLIC DINUCLEOTIDE CONJUGATES FOR CYTOKINE INDUCTION | INVIVOGEN (FR) | 2022-10-27 | — | — | US | disclosed |
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | TP53, NQO1, SHMT2 | MAPT 1762/4885KDM4E 3258/4885RAB9A 1412/4885 |
| US-11730817-B2 | Pro-cyclic dinucleotides and pro-cyclic dinucleotide conjugates for cytokine induction | STING1, CGAS, TLR9 | MAPT 4689/4885KDM4E 4445/4885RAB9A 1716/4885 |
| US-20220339287-A9 | PRO-CYCLIC DINUCLEOTIDES AND PRO-CYCLIC DINUCLEOTIDE CONJUGATES FOR CYTOKINE INDUCTION | STING1, CGAS, TLR9 | MAPT 4689/4885KDM4E 4445/4885RAB9A 1716/4885 |
| US-20230116913-A2 | PRO-CYCLIC DINUCLEOTIDES AND PRO-CYCLIC DINUCLEOTIDE CONJUGATES FOR CYTOKINE INDUCTION | STING1, CGAS, TLR9 | MAPT 4689/4885KDM4E 4445/4885RAB9A 1716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.